GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general med...
Pediatric Epilepsy Trial in Subjects 1-24 Months
- Conditions
- First Posted Date
- 2002-08-15
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 177
- Registration Number
- NCT00043875
- Locations
- πΉπ·
GSK Investigational Site, Ankara, Turkey
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
- Conditions
- First Posted Date
- 2002-08-15
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00043862
- Locations
- πΊπΈ
GSK Investigational Site, Wausau, Wisconsin, United States
Prevention Of Recurrence Of Atrial Fibrillation
- First Posted Date
- 2002-07-12
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 520
- Registration Number
- NCT00041496
ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST)
- First Posted Date
- 2002-07-12
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 343
- Registration Number
- NCT00041509
A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).
- First Posted Date
- 2002-06-10
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1309
- Registration Number
- NCT00038961
Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure
- Conditions
- First Posted Date
- 2001-10-16
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 330
- Registration Number
- NCT00025727
- Locations
- πΊπΈ
Bach and Godofsky, Bradenton, Florida, United States
πΊπΈTherafirst Med Ctr, Fort Lauderdale, Florida, United States
πΊπΈRush Med College / Dept of Infectious Diseases, Chicago, Illinois, United States
Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 400
- Registration Number
- NCT00011895
- Locations
- πΊπΈ
Therapeutic Concepts, Houston, Texas, United States
πΊπΈDiversified Med Practices, PA, Houston, Texas, United States
πΊπΈInfectious Diseases Associates of Houston, Houston, Texas, United States